Clearmind Medicine Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs

Reuters

02/20

<a href="https://laohu8.com/S/CMND">Clearmind Medicine</a> Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs

Clearmind Medicine Inc. reported progress related to its proprietary non-hallucinogenic neuroplastogen MEAI (5-Methoxy-2-aminoindane), including continued advancement of an FDA-approved Phase I/IIa clinical trial in alcohol use disorder. The company said multiple cohorts have been completed and that trial data readouts will be presented in the future. Clearmind also cited preclinical obesity findings for MEAI published in ACS Pharmacology & Translational Science and noted new patent applications and a collaboration with Polyrizon to develop an intranasal formulation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602191305PR_NEWS_USPR_____LN91475) on February 19, 2026, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2612628286"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612628286\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612628286?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 02:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612628286","market":"us","top_or_hot":-1,"title":"Clearmind Medicine Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CMND\">Clearmind Medicine</a> Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CMNDD\">Clearmind Medicine Inc.</a> reported progress related to its proprietary non-hallucinogenic neuroplastogen MEAI (5-Methoxy-2-aminoindane), including continued advancement of an FDA-approved Phase I/IIa clinical trial in alcohol use disorder. The company said multiple cohorts have been completed and that trial data readouts will be presented in the future. Clearmind also cited preclinical obesity findings for MEAI published in ACS Pharmacology &amp; Translational Science and noted new patent applications and a collaboration with Polyrizon to develop an intranasal formulation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CMNDF\">Clearmind Medicine Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602191305PR_NEWS_USPR_____LN91475) on February 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clearmind Medicine Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClearmind Medicine Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-02-20 02:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CMND\">Clearmind Medicine</a> Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CMNDD\">Clearmind Medicine Inc.</a> reported progress related to its proprietary non-hallucinogenic neuroplastogen MEAI (5-Methoxy-2-aminoindane), including continued advancement of an FDA-approved Phase I/IIa clinical trial in alcohol use disorder. The company said multiple cohorts have been completed and that trial data readouts will be presented in the future. Clearmind also cited preclinical obesity findings for MEAI published in ACS Pharmacology &amp; Translational Science and noted new patent applications and a collaboration with Polyrizon to develop an intranasal formulation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CMNDF\">Clearmind Medicine Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602191305PR_NEWS_USPR_____LN91475) on February 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL8bRMS7:1","article_id":"2612628286","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612628286","pubTimestamp":1771524345,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Clearmind Medicine Inc. reported progress related to its proprietary non-hallucinogenic neuroplastogen MEAI , including continued advancement of an FDA-approved Phase I/IIa clinical trial in alcohol use disorder. The company said multiple cohorts have been completed and that trial data readouts will be presented in the future. Clearmind also cited preclinical obesity findings for MEAI published in ACS Pharmacology & Translational Science and noted new patent applications and a collaboration with Polyrizon to develop an intranasal formulation.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CMND":"Clearmind Medicine, Inc.","PLRZ":"Polyrizon Ltd."},"translate_title":"随着下一代减肥治疗市场超越GLP-1药物，Clearmind Medicine报告MEAI的进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMND":0.9,"PLRZ":0.9},"content_text":"Clearmind Medicine Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs\n    \n\nClearmind Medicine Inc. reported progress related to its proprietary non-hallucinogenic neuroplastogen MEAI (5-Methoxy-2-aminoindane), including continued advancement of an FDA-approved Phase I/IIa clinical trial in alcohol use disorder. The company said multiple cohorts have been completed and that trial data readouts will be presented in the future. Clearmind also cited preclinical obesity findings for MEAI published in ACS Pharmacology & Translational Science and noted new patent applications and a collaboration with Polyrizon to develop an intranasal formulation.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602191305PR_NEWS_USPR_____LN91475) on February 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}